Literature DB >> 16645205

Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas.

Tamotsu Sugai1, Wataru Habano, Yu-Fei Jiao, Mitsunori Tsukahara, Yuichiro Takeda, Koki Otsuka, Shin-ichi Nakamura.   

Abstract

To clarify distinct genetic profiles of colorectal cancers based on tumor location (left- and right-sided), we evaluated the status of loss of heterozygosity (LOH), CpG islands methylation phenotype (CIMP), microsatellite instability (MSI), and mutations of p53, Ki-ras, and APC genes in 119 colorectal cancers. Statuses of LOH (at 5q, 8p, 17p, 18q, and 22q), MSI, and CIMP (MINT1, MINT2, MINT31, MLH-1, MGMT, p14, p16, and RASSF1A) were determined using microsatellite polymerase chain reaction and methylation-specific polymerase chain reaction coupled with a crypt isolation method, respectively. In addition, mutations of p53, Ki-ras, and APC genes were also examined. LOH, MSI, and CIMP status allowed us to classify samples into two groups: low or negative and high or positive. Whereas the frequency of p53 mutations in the LOH-high status was significantly higher in left-sided cancers than in right-sided cancers, CIMP-high in the LOH-high status and MSI-positive status were more frequently found in right-sided cancers compared with left-sided cancers. Finally, location-specific methylated loci were seen in colorectal cancers: type I (dominant in right-sided cancer) and type II (common in both segments of cancer). Our data confirm that distinct molecular pathways to colorectal cancer dominate in the left and right sides of the bowel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16645205      PMCID: PMC1867579          DOI: 10.2353/jmoldx.2006.050052

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  34 in total

1.  Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.

Authors:  W A Bleeker; V M Hayes; A Karrenbeld; R M Hofstra; J Hermans; C C Buys; J T Plukker
Journal:  Am J Gastroenterol       Date:  2000-10       Impact factor: 10.864

2.  CpG island methylation in aberrant crypt foci of the colorectum.

Authors:  Annie On-On Chan; Russell R Broaddus; Patrick S Houlihan; Jean-Pierre J Issa; Stanley R Hamilton; Asif Rashid
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

3.  Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability.

Authors:  Y Miyakura; K Sugano; F Konishi; A Ichikawa; M Maekawa; K Shitoh; S Igarashi; K Kotake; Y Koyama; H Nagai
Journal:  Gastroenterology       Date:  2001-12       Impact factor: 22.682

4.  Frequent allelic imbalance at the ATM locus in DNA multiploid colorectal carcinomas.

Authors:  T Sugai; W Habano; N Uesugi; Y F Jiao; S I Nakamura; T Yoshida; T Higuchi
Journal:  Oncogene       Date:  2001-09-20       Impact factor: 9.867

5.  Genetic alterations in DNA diploid, aneuploid and multiploid colorectal carcinomas identified by the crypt isolation technique.

Authors:  T Sugai; W Habano; S Nakamura; H Sato; N Uesugi; H Takahashi; Y Jiao; T Yoshida; C Itoh
Journal:  Int J Cancer       Date:  2000-11-15       Impact factor: 7.396

6.  CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.

Authors:  Nicholas Hawkins; Mark Norrie; Kay Cheong; Elisa Mokany; Su-Lyn Ku; Alan Meagher; Terence O'Connor; Robyn Ward
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

7.  Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability.

Authors:  V L Whitehall; M D Walsh; J Young; B A Leggett; J R Jass
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

8.  Prognostic significance of p53 mutations in colon cancer at the population level.

Authors:  Wade S Samowitz; Karen Curtin; Khe-ni Ma; Sandra Edwards; Donna Schaffer; Mark F Leppert; Martha L Slattery
Journal:  Int J Cancer       Date:  2002-06-01       Impact factor: 7.396

9.  CpG island methylation in colorectal adenomas.

Authors:  A Rashid; L Shen; J S Morris; J P Issa; S R Hamilton
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

10.  Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer.

Authors:  W A Bleeker; V M Hayes; A Karrenbeld; R M Hofstra; E Verlind; J Hermans; S Poppema; C H Buys; J T Plukker
Journal:  Dis Colon Rectum       Date:  2001-03       Impact factor: 4.585

View more
  55 in total

1.  Genomic and epigenomic integration identifies a prognostic signature in colon cancer.

Authors:  Joo Mi Yi; Mashaal Dhir; Leander Van Neste; Stephanie R Downing; Jana Jeschke; Sabine C Glöckner; Marilia de Freitas Calmon; Craig M Hooker; Juan M Funes; Chris Boshoff; Kim M Smits; Manon van Engeland; Matty P Weijenberg; Christine A Iacobuzio-Donahue; James G Herman; Kornel E Schuebel; Stephen B Baylin; Nita Ahuja
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

2.  The Relationship between the Methylated Septin-9 DNA Blood Test and Stool Occult Blood Test for Diagnosing Colorectal Cancer in Taiwanese People.

Authors:  Chung-Hung Chen; Sheng-Lei Yan; Tsung-Hsun Yang; Shih-Feng Chen; Yung-Hsiang Yeh; Jing-Jim Ou; Chien-Hua Lin; Yueh-Tsung Lee; Chien-Hua Chen
Journal:  J Clin Lab Anal       Date:  2016-07-08       Impact factor: 2.352

Review 3.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

4.  Temporal trends in incidence and mortality rates for colorectal cancer by tumor location: 1975-2007.

Authors:  Amanda I Phipps; John Scoggins; Mary Anne Rossing; Christopher I Li; Polly A Newcomb
Journal:  Am J Public Health       Date:  2012-01-19       Impact factor: 9.308

5.  Analysis of molecular alterations in laterally spreading tumors of the colorectum.

Authors:  Tamotsu Sugai; Wataru Habano; Ryo Takagi; Hiroo Yamano; Makoto Eizuka; Noriyuki Arakawa; Yayoi Takahashi; Eiichiro Yamamoto; Keisuke Kawasaki; Syunichi Yanai; Kazuyuki Ishida; Hiromu Suzuki; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2016-10-04       Impact factor: 7.527

Review 6.  From tumour heterogeneity to advances in precision treatment of colorectal cancer.

Authors:  Cornelis J A Punt; Miriam Koopman; Louis Vermeulen
Journal:  Nat Rev Clin Oncol       Date:  2016-12-06       Impact factor: 66.675

7.  Colorectal cancer following negative colonoscopy: is 5-year screening the correct interval to recommend?

Authors:  Steven K Nakao; Steven Fassler; Iswanto Sucandy; Soo Kim; D Mark Zebley
Journal:  Surg Endosc       Date:  2012-10-10       Impact factor: 4.584

8.  Next-generation narrow band imaging system for colonic polyp detection: a prospective multicenter randomized trial.

Authors:  Takahiro Horimatsu; Yasushi Sano; Shinji Tanaka; Takuji Kawamura; Shoichi Saito; Mineo Iwatate; Shiro Oka; Koji Uno; Kenichi Yoshimura; Hideki Ishikawa; Manabu Muto; Hisao Tajiri
Journal:  Int J Colorectal Dis       Date:  2015-04-30       Impact factor: 2.571

9.  Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer.

Authors:  P Mokarram; M Zamani; S Kavousipour; F Naghibalhossaini; C Irajie; M Moradi Sarabi; S V Hosseini
Journal:  Mol Biol Rep       Date:  2012-12-28       Impact factor: 2.316

10.  Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.

Authors:  Felipe De Sousa E Melo; Xin Wang; Marnix Jansen; Evelyn Fessler; Anne Trinh; Laura P M H de Rooij; Joan H de Jong; Onno J de Boer; Ronald van Leersum; Maarten F Bijlsma; Hans Rodermond; Maartje van der Heijden; Carel J M van Noesel; Jurriaan B Tuynman; Evelien Dekker; Florian Markowetz; Jan Paul Medema; Louis Vermeulen
Journal:  Nat Med       Date:  2013-04-14       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.